Rivaldo – rivastigmine with a good safety profile Review article
Article Sidebar
Main Article Content
Abstract
Alzheimer disease is the most common form of dementia and represents 60–70% percent of all cases. Patients with Parkinson’s disease have also very high risk of dementia development. Rivastigmine is approved for the treatment of mild and moderate dementia in the course of Alzheimer disease and in the course of Parkinson’s disease. An postmarketing, open label, non-randomized, multicenter observational trial was performed to evaluate safety profile and tolerance of new oral generic rivastigmine formulation – Rivaldo®. Trial evaluated 2196 patients with Alzheimer’s disease and 111 patient with dementia in the course of Parkinson’s disease. Data obtained in this observational trial confirms that Rivaldo® has a good safety profile. The drug is well tolerated and accepted by patients.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright: © Medical Education sp. z o.o. License allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
2. Aarsland D, Andersen K, Larsen JP et al. Risk of dementia in Parkinson disease: a community-based, prospective study. Neurology 2000; 54: S10-15.
3. Cummings JL. Intelectual impairment in Parkinson’s disease: clinical, biological and clinical correlates. J Geriatr Psychiatr Neurol 1988; 1: 24-36.
4. Parnowski T. Postępy terapii zaburzeń procesów poznawczych w otępieniu. Terapia 2003; 11: 27-30.
5. Safety and tolerability of transdermal and oral rivastigmine in Alzheimer’s disease and Parkinson’s disease dementia. Expert Opin Drug Saf 2010; 9: 167-176.
6. Sramek JJ, Anand R, Wardle TS et al. Safety/tolerability trial of SDZ ENA 713 in patients with probable Alzheimer’s disease. Life Sci 1996; 58: 1201-1207.
7. Corey-Bloom J, Anand R, Veach J for the ENA 713 (rivastigmine tartrate) B352 Study Group. A randomized trial evaluating the efficacy and safety ofENA-713, a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer’s disease. lnt J Geriatr Psychopharmacol 1998; 1: 55-65.
8. Rősler M, Anand R, Cicin-Sain A et al. Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomised controlled trial. BMJ 1999; 318: 633-638.
9. Emre M, Aarsland D, Albanese A et al. Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med 2004; 351: 2509-2518.
10. Rivaldo – charakterystyka produktu leczniczego.
11. Olszanecka-Glinianowicz M. Raport końcowy z programu: ocena profilu bezpieczeństwa stosowania rywastygminy preparatu Rivaldo w populacji polskiej.